Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms

Juan Manuel Carreño; Damodara Rao Mendu; Viviana Simon; Masood A Shariff; Gagandeep Singh; Vidya Menon; Florian Krammer

doi:10.1016/j.isci.2021.102937

Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms

iScience. 2021 Sep 24;24(9):102937. doi: 10.1016/j.isci.2021.102937. Epub 2021 Jul 31.

Authors

Juan Manuel Carreño¹, Damodara Rao Mendu², Viviana Simon^{1

3

4}, Masood A Shariff⁵, Gagandeep Singh¹, Vidya Menon⁵, Florian Krammer¹

Affiliations

¹ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
² Clinical Microbiology Laboratory, Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
³ Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
⁴ The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
⁵ Department of Internal Medicine, NYC Health + Hospitals/Lincoln, The Bronx, NY 10451, USA.

Abstract

Current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests are based on the full-length spike (S), the receptor-binding domain (RBD), or the nucleoprotein (NP) as substrates. Here, we used samples from healthcare workers (HCWs) to perform a longitudinal analysis of the antibody responses using a research-grade RBD and spike-based enzyme-linked immunosorbent assay (ELISA), a commercial RBD and spike-based ELISA, and a commercial NP-based chemiluminescent microparticle immunoassay. Seroprevalence ranged around 28% early during the pandemic and a good correlation was observed between RBD and spike-based ELISAs. Modest correlations were observed between NP and both RBD and spike-based assays. The antibody levels in HCWs declined over time; however, the overall seroprevalence measured by RBD and spike-based assays remained unchanged, while the seroprevalence of NP-reactive antibodies significantly declined. Moreover, RBD and spike-based assays effectively detected seroconversion in vaccinees. Overall, our results consolidate the strength of different serological assays to assess the magnitude and duration of antibodies to SARS-CoV-2.

Keywords: Immunology; Virology.

Abstract

Grants and funding